Clinical and mucosal parameters in control animals, in EHEC infected animals, and in EHEC infected animals treated with the LTB4 synthesis inhibitor MK-886
| Control | Infected | Infected+MK-886 | |
| Weight gain (g) | 66 (5) | 59 (8) | 34 (5)1-a |
| Diarrhoea score | 0 | 2.0 (0.3)1-a | 2.7 (0.1)1-a |
| LTB4(pg/mg mucosa) | 3.2 (0.7) | 8.4 (1.4)1-a | 2.0 (0.4)a b |
| MPO activity (U/g mucosa) | 2.9 (0.7) | 33.9 (3.5)1-a | 36.6 (7.4)1-a |
| Histology score | 0.3 (0.1) | 5.4 (0.3)1-a | 5.3 (0.3)1-a |
Data are mean (SEM) of n=9–24.
↵1-a p<0.05 compared with control;
1-b p<0.05 compared with infected group.
MPO, myeloperoxidase.